Τίτλος:
Management of patients with difficult-to-treat multiple myeloma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Newer treatments for multiple myeloma (MM) have improved response rates and survival for many patients. However, MM remains challenging to treat due to the propensity for multiple relapses, cumulative and emergent toxicities from prior therapies and increasing genomic complexity that arises due to clonal evolution. In particular, patients with relapsed/refractory MM often require increased complexity of treatment, yet still experience poorer outcomes compared with patients who are newly diagnosed. Additionally, several patient subgroups, including those with extramedullary disease and patients who are frail and/or have multiple comorbidities, have an unfavorable prognosis and remain undertreated. This review (based on an Updates-in-Hematology session at the 25th European Hematology Association Annual Congress 2020) discusses the management of these difficult-to-treat patients with MM. © 2021 Future Medicine Ltd.. All rights reserved.
Συγγραφείς:
Richter, J.
Ramasamy, K.
Rasche, L.
Bladé, J.
Zweegman, S.
Davies, F.
Dimopoulos, M.
Περιοδικό:
Future Oncology
Εκδότης:
Future Medicine Ltd
Λέξεις-κλειδιά:
bendamustine; bortezomib; carfilzomib; ciltacabtagene autoleucel; cisplatin; cyclophosphamide; daratumumab; dexamethasone; elotuzumab; etoposide; iberdomide; idecabtagene vicleucel; ixazomib; lenalidomide; melphalan flufenamide; pacanalotamab; panobinostat; pavurutamab; placebo; pomalidomide; prednisone; selinexor; talquetamab; teclistamab; venetoclax, autologous stem cell transplantation; cancer growth; cancer incidence; cancer prognosis; cancer recurrence; cancer therapy; comorbidity; Conference Paper; diffusion weighted imaging; frailty; geriatric patient; high risk patient; human; multiple myeloma; nuclear magnetic resonance imaging; positron emission tomography-computed tomography; priority journal; progression free survival; treatment planning; tumor invasion; clinical trial (topic); disease management; immunotherapy; multiple myeloma; organization; pathology; procedures; prognosis; treatment outcome; tumor recurrence, Clinical Trials as Topic; Congresses as Topic; Disease Management; Humans; Immunotherapy; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Treatment Outcome
DOI:
10.2217/fon-2020-1280
